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Summary
Background: Oral follow-up therapy is problematic in moulds with reduced azole-
susceptibility, such as azole-resistant Aspergillus fumigatus infection. Currently, only 
intravenous liposomal amphotericin B (L-AmB) is advocated by guidelines for the 
treatment of azole-resistant aspergillosis infections. Preclinical research indicates 
that high-dose posaconazole (HD-POS) might be a feasible option provided that high 
drug exposure (ie POS serum through levels >3 mg/L) can be achieved and is safe.
Objectives: To describe our experience with the use of oral HD-POS as treatment 
strategies for patients infected with pathogens with a POS MIC close to the clinical 
breakpoint.
Patients/Methods: We review evidence supporting the use of HD-POS and describe 
our experience on safety and efficacy in 16 patients. In addition, we describe the ad-
verse events (AE) observed in 25 patients with POS concentrations at the higher end 
of the population distribution during treatment with the licensed dose.
Results: Sixteen patients were treated intentionally with HD-POS for voriconazole-
resistant invasive aspergillosis (7/16), mucormycosis (4/16), salvage therapy for IA 
(4/16) and IA at a sanctuary site (spondylodiscitis) in 1. Grade 3-4 AEs were observed 
in 6, and all of them were considered at least possibly related. Grade 3-4 AEs were 
observed in 5 of the 25 patients with spontaneous high POS serum through levels 
considered at least possibly related using Naranjo scale.
Conclusions: High-dose posaconazole is a treatment option if strict monitoring for 
both exposure and for AE is possible.
K E Y W O R D S
antifungal susceptibility, antimycotic chemotherapy, aspergillosis
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1  | INTRODUC TION
Invasive aspergillosis (IA) in patients with haematological malignancies is 
associated with a mortality of 20%-30%.1,2 Triazole resistance is increas-
ingly reported in different countries through culture-based surveillance 
studies3 and is associated with a much higher mortality of 50%-88%.4,5 
In 2015, a consensus meeting on the management of azole-resistant IA 
was organised6 and liposomal amphotericin B (L-AmB) was advocated 
as the preferred therapy but has obvious toxicity limitations and can 
only be administered intravenously. Treatment of IA has to be contin-
ued for a minimum of 6-12 weeks but occasionally much longer.7 Other 
treatment options are therefore urgently needed. Phase II studies on 
new antifungals are just about to start and subsequent phase III studies 
typically take 3 or 4 years to complete. Therefore, these drugs will not 
provide a short term solution. Targeting high-exposure posaconazole 
(POS) may be a potential oral step-down treatment option for azole-re-
sistant IA and other difficult-to-treat mould infections.
Posaconazole is approved in patients with haematological ma-
lignancies both for prophylaxis and treatment of refractory IA or 
when intolerance to first-line agents occurs.8,9 The agent is avail-
able as oral suspension, a delayed-release tablet and an intravenous 
formulation. Oral absorption of POS oral suspension is affected by 
food and gastric pH. In contrast, POS tablets contain the active drug 
mixed with a pH-sensitive polymer10 and this polymer releases the 
drug in the intestines, causing threefold increased exposures com-
pared to POS oral suspension.11
Therapeutic drug monitoring (TDM) has been widely imple-
mented to assess therapeutic efficacy of POS oral suspension 
but its usefulness is in a state of flux following the introduction 
of the new POS formulations specifically in the setting of prophy-
laxis.12-14 Current guidelines recommend a Ctrough concentration of 
≥0.7 mg/L for prophylaxis and >1.0 mg/L for primary and >1.25 mg/L 
for salvage therapy,15 although these concentrations were deter-
mined independent of the susceptibility of the infecting pathogen.13
These targets have been derived for susceptible pathogens and are 
not valid for pathogens with attenuated susceptibilities. A different ap-
proach is needed to optimise treatment in case of reduced susceptibility.
Preclinical research indicates that high-dose posaconazole 
(HD-POS) might be a feasible option provided that high drug ex-
posure (ie POS serum through levels >3 mg/L) can be achieved and 
is safe. Hence, we argued that oral high-dose treatment strategies 
might be feasible to treat pathogens with relatively low MICs/MICs 
just above the clinical breakpoint (low-resistant). Human data on 
the treatment of pathogens with reduced susceptibility as well as 
safety of POS Ctrough concentrations of >3 mg/L are sparse.
Here, we review the evidence supporting the use of HD-POS and 
describe our experience on safety and efficacy in 16 patients. In ad-
dition, we describe the adverse events (AE) observed in 25 patients 
with POS concentrations at the higher end of the population distri-
bution during treatment with the licensed dose.
2  | PATIENTS/METHODS
We set out to explore safety of HD-POS and retrospectively 
collected clinical and laboratory data of patients from 2 Dutch 
academic medical centres (Erasmus University Medical Centre, 
Adverse event Grade 1 Grade 2 Grade 3 Grade 4 Grade 5
Diarrhoea 1     
Nausea  1    
Vomiting 3     
Increased hepatic enzymes 4 1 13 25,7  
Cardiac troponin T increased   16   
Electrocardiogram QTc corrected 
interval prolonged
1 1 16   
Leukopenia    14  
Hypokalaemia 3 3    
Hyperkalaemia 1     
Headache  1    
Delirium 1  12   
Alopecia 1     
Hypertension  2    
Heart failure   15   
Rash 1     
Note: Digits refer to the number of patients in whom these AEs have been documented. 
Prolongation in the QTc interval was assessed by comparing electrocardiograms obtained at 
baseline and during HD-POS treatment, if available.
Naranjo16 adverse drug reaction probability scale: >9: definite, 5 to 8: probable, 1-4: possible. −3 to 
0: doubtful.
TA B L E  1   Adverse events of 16 
patients receiving intentionally HD-POS 
graded accordingly to the Common 
Terminology Criteria for Adverse Events 
(version 4.03)
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Rotterdam and Radboud University Medical Centre, Nijmegen) in 
which POS Ctrough concentrations >3 mg/L had been documented 
in two different populations. All patients were in care by one of the 
authors of this paper. Data were extracted and reviewed by JB and 
AS Group 1 consisted of patients intentionally treated with HD-
POS targeting POS Ctrough concentrations >3 mg/L and Group 2 
were patients that reached POS Ctrough concentrations >3 mg/L 
with the licensed dose. We focused on AEs (related or unrelated 
to POS) described in the patient files and laboratory data. Data 
from these patients were reviewed for toxicities according to the 
Common Terminology Criteria for Adverse Events (CTCAE) ver-
sion 4.03. An AE was defined as unfavourable or unintended sign 
or symptom while the patient was treated with POS, whether or 
not the sign or symptom was related to POS. The Naranjo scale 
was used to determine for the assessment of causality of potential 
AE with POS. This is a questionnaire for determining a potential 
likelihood that an adverse drug reaction is actually linked to a drug. 
Probability is assigned using a scoring system with the following 
possible results: definite, probable, possible of doubtful.16 Medians 
and 25th to 75th inter-quartile ranges were used for statistic de-
scriptions. This type of research does not fall under the Dutch law 
of research on human subjects. However, to safeguard the pri-
vacy of the patients, the data were stored anonymously after data 
extraction.
3  | RESULTS
3.1 | Group 1
Sixteen patients were treated intentionally with HD-POS for 
voriconazole-resistant IA (7/16), mucormycosis (4/16), salvage 
TA B L E  2   Underlying condition, IFD, A fumigatus genotype and phenotype, and outcome in 16 patients treated with high-dose  
posaconazole (HD-POS)
Patient
Age 
(years) Underlying disease IFD, classification Reason HD-POS Sample with culture Aspergillus PCR result MIC(mg/L)a POS concentration: calculated target Outcome
       ITZ VCZ POS ISA Highest C Calculated Target  
1 69 Mixed dust pneumoconiosis CPA Resistant strain Sputum: A fumigatus TR46/Y121F/T289A >16 8 1 4 3.8 6.18-6.66 Alive
2 51 AML, AlloTx IPA, probable Resistant strain No positive culture Y121F/T289A in BAL     6.1  Dead
3 18 ALL IPA, proven (cerebral) Resistant strain Sputum: A fumigatus TR34/L98H 16 8 2 8 6 >10 Alive
4 46 SOT (kidney), PTLD IPA, probable Resistant strain BAL: A fumigatus TR34/L98H >16 4 0.5 8 0.2
c 3.09-3.33 Dead
5 69 AML IPA, probable Resistant strain No positive culture TR34/L98H in BAL     4  Dead
6 61 No relevant CPA Resistant strain BAL: A fumigatus  >16 8 1 8 6.6 6.18-6.66 Alive
7 32 SOT (lung) Pulmonary mucormycosis, 
proven
Mucormycosis Lung: Rhizopus species  1 8 0.25 1 3.8 1.44-1.55 Alive
8 17 ALL IPA, probable Mixed infection (R/S) BAL: A fumigatus R and S  >16 4 0.5 8 5.6 3.09-3.33 Alive
9 50 AML, AlloTx Mucormycosis, probable Mucormycosis No positive culture      5.2  Alive
10 58 SLE with pancytopenia Mucormycosis, proven Mucormycosis Liver biopsy: microscopy: hyphy.  
No positive culture. Spleen  
biopsy PCR positive
PCR: Rizomucor pussilus     5.0  Alive
11 67 DM type II Mucormycosis, probable 
(skin)
Mucormycosis Tissue sample wound: Rhizopus  
oryzae
 0.25 8 0.25 1 3.5 1.44-1.55 Alive
12 2 ALL Mucormycosis, proven Mucormycosis Multiple skin biopsies:  
Lichtheimia corymbifera
 0.5 16 0.5 >16 6.6 3.09-3.33 Alive
13 50 No relevant IA, proven Sanctuary sites 
infection
Spinal biopsy: A fumigatus  0.25b 0.25b 0.063b 0.5b 3.6  Alive
14 68 AML IPA, probable Salvage No positive culture      3.8  Dead
15 65 AML IPA, probable Salvage Sputum: A nidulans Wild-type A fumigatus in BAL 0.25 0.25 0.25 0.5 3.1 1.44-1.55 Dead
16 8 ALL IPA, proven Salvage A terreus Lobectomy, lung tissue: A terreus Lung biopsy: Aspergillus Species 0.125 1 0.031 1 4.7  Alive
Note: Calculated target Ctrough based on the MIC is taken from Seyedmousavi et al28
Abbreviations: AlloTx, allogeneic stem cell transplant; C, concentration; CPA, chronic pulmonary aspergillosis; HD-POS, high-dose posaconazole;  
IA, invasive aspergillosis; IFD, invasive fungal diseases; IPA, Invasive pulmonary aspergillosis; ISA, isavuconazole; ITZ, Itraconazole;  
POS, posaconazole; PTLD, post-transplant lymphoproliferative disease; R, resistant; S, Susceptible; SOT, solid organ transplantation;  
VCZ, voriconazole.
aMIC was determined according to the EUCAST method for susceptibility testing of moulds (version 9.2). Patients were classified following the  
revised definitions of the European Organization for Research and Treatment of Cancer/Mycosis Study Group (EORTC/MSG). 42 
bMIC was determined according to the CLSI method for susceptibility testing of moulds(M38-A2) 
cthis patient was included because the patient was treated with POS 400 mg BID despite the low Ctrough level. 
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therapy for IA (4/16) and IA at a sanctuary site (spondylodiscitis) 
in 1. The median POS dose given was 600 (IQR 400 750) mg daily 
when the POS Ctrough concentrations of > 3 mg/L were reached 
after a median of 8 (IQR 6.40) days. Ten patients had significantly 
higher Ctrough concentration (above 4 mg/L) and 6 patients 
had Ctrough concentrations between 3.0 and 4.0 mg/L and on 
average patients had these concentrations for a median 76 days 
(IQR 20 162). Thirteen patients received POS tablet, 1 patient 
posaconazole-oral suspension (POS-OS) and 2 patients a combin 
ation of formulations. AEs are described in Table 1. Grade 3-4 
AEs were observed in 6 patients, and all of them were consid-
ered at least possibly related using Naranjo scale. In 3 out of 16 
patients, the treatment was stopped following an AE: arterial 
hypertension (grade 2), QTc prolongation, cardiac troponin T in-
creased and left ventricular failure (grade 3) and leukocytopenia 
(grade 4).
3.2 | Efficacy
Of the 7 patients with azole-resistant IA treated with HD-POS, 4 
survived while 3 died from their underlying disease but unrelated 
to the IA. In two patients, HD-POS was used as salvage therapy. 
One patient with IA caused by Aspergillus terreus was treated with 
HD-POS because serum galactomannan levels increased under con-
ventional dosage which is a predictor of poor outcome (Table 2). All 
patients with mucormycosis survived.
3.3 | Group 2
This group consisted of 25 patients. The median POS Ctrough 
concentration was 4.3 mg/L (IQR 3.5-6.0). 19, 5 and 1 patient re-
ceived POS tablet, POS-OS and the IV formulation, respectively. 
TA B L E  2   Underlying condition, IFD, A fumigatus genotype and phenotype, and outcome in 16 patients treated with high-dose  
posaconazole (HD-POS)
Patient
Age 
(years) Underlying disease IFD, classification Reason HD-POS Sample with culture Aspergillus PCR result MIC(mg/L)a POS concentration: calculated target Outcome
       ITZ VCZ POS ISA Highest C Calculated Target  
1 69 Mixed dust pneumoconiosis CPA Resistant strain Sputum: A fumigatus TR46/Y121F/T289A >16 8 1 4 3.8 6.18-6.66 Alive
2 51 AML, AlloTx IPA, probable Resistant strain No positive culture Y121F/T289A in BAL     6.1  Dead
3 18 ALL IPA, proven (cerebral) Resistant strain Sputum: A fumigatus TR34/L98H 16 8 2 8 6 >10 Alive
4 46 SOT (kidney), PTLD IPA, probable Resistant strain BAL: A fumigatus TR34/L98H >16 4 0.5 8 0.2
c 3.09-3.33 Dead
5 69 AML IPA, probable Resistant strain No positive culture TR34/L98H in BAL     4  Dead
6 61 No relevant CPA Resistant strain BAL: A fumigatus  >16 8 1 8 6.6 6.18-6.66 Alive
7 32 SOT (lung) Pulmonary mucormycosis, 
proven
Mucormycosis Lung: Rhizopus species  1 8 0.25 1 3.8 1.44-1.55 Alive
8 17 ALL IPA, probable Mixed infection (R/S) BAL: A fumigatus R and S  >16 4 0.5 8 5.6 3.09-3.33 Alive
9 50 AML, AlloTx Mucormycosis, probable Mucormycosis No positive culture      5.2  Alive
10 58 SLE with pancytopenia Mucormycosis, proven Mucormycosis Liver biopsy: microscopy: hyphy.  
No positive culture. Spleen  
biopsy PCR positive
PCR: Rizomucor pussilus     5.0  Alive
11 67 DM type II Mucormycosis, probable 
(skin)
Mucormycosis Tissue sample wound: Rhizopus  
oryzae
 0.25 8 0.25 1 3.5 1.44-1.55 Alive
12 2 ALL Mucormycosis, proven Mucormycosis Multiple skin biopsies:  
Lichtheimia corymbifera
 0.5 16 0.5 >16 6.6 3.09-3.33 Alive
13 50 No relevant IA, proven Sanctuary sites 
infection
Spinal biopsy: A fumigatus  0.25b 0.25b 0.063b 0.5b 3.6  Alive
14 68 AML IPA, probable Salvage No positive culture      3.8  Dead
15 65 AML IPA, probable Salvage Sputum: A nidulans Wild-type A fumigatus in BAL 0.25 0.25 0.25 0.5 3.1 1.44-1.55 Dead
16 8 ALL IPA, proven Salvage A terreus Lobectomy, lung tissue: A terreus Lung biopsy: Aspergillus Species 0.125 1 0.031 1 4.7  Alive
Note: Calculated target Ctrough based on the MIC is taken from Seyedmousavi et al28
Abbreviations: AlloTx, allogeneic stem cell transplant; C, concentration; CPA, chronic pulmonary aspergillosis; HD-POS, high-dose posaconazole;  
IA, invasive aspergillosis; IFD, invasive fungal diseases; IPA, Invasive pulmonary aspergillosis; ISA, isavuconazole; ITZ, Itraconazole;  
POS, posaconazole; PTLD, post-transplant lymphoproliferative disease; R, resistant; S, Susceptible; SOT, solid organ transplantation;  
VCZ, voriconazole.
aMIC was determined according to the EUCAST method for susceptibility testing of moulds (version 9.2). Patients were classified following the  
revised definitions of the European Organization for Research and Treatment of Cancer/Mycosis Study Group (EORTC/MSG). 42 
bMIC was determined according to the CLSI method for susceptibility testing of moulds(M38-A2) 
cthis patient was included because the patient was treated with POS 400 mg BID despite the low Ctrough level. 
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Posaconazole was given to 18 and 7 patients for prophylaxis and 
treatment, respectively. All observed AEs are described in Table 3. 
The most frequently observed AE were hypokalaemia in eight pa-
tients and neurological in six patients (headache, convulsions). Grade 
3-4 AEs were observed in 5, and all of them were considered at least 
possibly related using Naranjo scale. In 8 of the 25 patients, the dos-
age was reduced. Follow-up Ctrough concentrations were between 
1.1 and 4.3 mg/L after dosage reduction.
4  | DISCUSSION
Little is known about the toxicity of patients attaining high POS 
Ctrough of >3 mg/L. The upper boundary level of average POS 
serum concentrations of 3.75 mg/L is set by the European Medicines 
Agency based on experience with the POS-OS and preclinical toxi-
cology findings.17 In this study, we reviewed the safety and tolerabil-
ity of HD-POS. In both group 1 and group 2, three patients were seen 
with a combination of hypertension and hypokalaemia that required 
antihypertensive therapy and potassium supplementation. The most 
striking case was a child treated with POS, L-AmB and micafungin for 
a proven aspergillosis following surgical removal of Aspergillus lesions 
in the spleen, left lung and right kidney. This patient developed sev-
eral hypertensive crises and developed hypokalaemia for which oral 
supplementation was needed. 8 months after POS treatment, the 
patient died due to a vasopressor refractory shock. During these hy-
pertensive crises, aldosterone could not be measured (<50 pmol/L) 
and renine was within normal range. In retrospect, POS may have 
caused the hypertension and hypokalaemia. Recently, a case of POS-
induced heart failure, hypertension and hypokalaemia was described 
with low renin and aldosterone levels. The inhibition of the enzyme 
11-beta-hydroxysteroid dehydrogenase 2 is suggested as the poten-
tial mechanism causing apparent mineralocorticoid excess.18-20 This 
enzyme is homeostatic regulator and damps mineralocorticoid activ-
ity by converting cortisol to cortisone.
The AE of HD-POS observed in this study are in line with pre-
vious reports of AE due to POS. A phase III study assessing PK and 
safety of POS tablet demonstrated that nausea and diarrhoea were 
the most common treatment-related AEs leading to POS discontin-
uation in 2% and 1%, respectively.21 Only 9 patients (10%) in this 
study attained an average Ctrough concentration between 2.5 and 
3.75 mg/L, and six patients (3%) reached Ctrough concentrations 
≥3.75 mg/L. No increase of AEs in patients with higher POS serum 
concentrations was observed but the study was not powered to 
detect such a relation. Very recently, PK and safety results from a 
phase 3 study of IV POS in patients at risk for invasive fungal disease 
were published. Six per cent of the patients had a steady-state con-
centration between >2.5 and ≤3.65 mg/L without signs of toxicity.22 
In a retrospective analysis of 64 patients receiving POS tablet as 
prophylaxis, median POS steady-state concentrations of 1.67 mg/L 
(0.52-3.83 mg/L) were documented. In 21% of the patients, a QTc 
 Grade 1 Grade 2 Grade 3 Grade 4 Grade 5
Adverse event      
Diarrhoea 4     
Nausea 4     
Vomiting 2     
Increased hepatic 
enzymes
2 3 14   
Electrocardiogram QT 
corrected interval 
prolonged
2 1    
GGT increased  1    
Anorexia 5 1    
Hyponatremia 2  11   
Hypokalaemia 7 1    
Headache 5     
Seizure  1    
Alopecia 2     
Hypertension  2 17 14  
Hypotension     17
Rash 3     
Note: Digits refer to the number of patients in whom these AEs have been documented. 
Refractory shock, rapidly fatal. Distributive shock most likely according to treating physician.
These grade 3 or 4 AE were considered at least possible related to POS.
Naranjo16 adverse drug reaction probability scale: >9: definite, 5 to 8: probable, 1-4: possible. −3 to 
0: doubtful.
TA B L E  3   Adverse events of 25 
patients receiving POS with high 
spontaneous concentration graded 
accordingly to the Common Terminology 
Criteria for Adverse Events(version 4.03)
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prolongation was observed and the median steady-state concentra-
tion was 2.04 mg/L.23 In a single-centre study, 343 courses of POS 
prophylaxis (IV or tablet) were assessed for safety and effectiveness. 
20% of these patients developed liver injury, mostly hyperbilirubin-
emia but this is often multifactorial. More importantly, grade 3-4 ele-
vations in hepatic enzymes were only observed in 2% of the patients 
without pre-existing liver injury with mostly spontaneous resolution 
despite treatment continuation.24 Thus, in the current literature, in-
formation about the toxicity of high POS serum concentrations is 
limited but no increase in the number of AEs was observed in pa-
tients with higher than average serum concentrations.
4.1 | Azole-resistant IA
The large majority of azole-resistant A fumigatus isolates har-
bour TR34/L98H or TR46/Y121F/T289A mutations in the cyp51A 
gene,25,26 encoding the cytochrome p450 sterol 14α-demethylase, 
the target of azoles. A fumigatus isolates carrying resistance-as-
sociated mutations have high minimal inhibitory concentrations 
(MICs) for itraconazole and/or voriconazole as well as isavucona-
zole.27 The MIC of POS often remains close to the susceptible pop-
ulation (ie MIC ≤0.5 to 1 mg/L).28 MIC levels of POS >0.25 mg/L 
are considered resistant according to the EUCAST breakpoint, but 
this is based on population susceptibility and on concentrations 
achieved with the POS-OS at licensed dose. Indeed, drug expo-
sure with POS-OS will marginally cover the A fumigatus wild-type 
population, let alone low-level POS-resistant isolates. Higher ex-
posures can be achieved with the newer formulations.13 The phar-
macodynamic-pharmacokinetic (PK-PD) relationships of POS have 
been studied in vivo. A murine model of IA indicated that low-level 
POS-resistant isolates can be treated when the POS exposure is 
increased. Two in vivo studies demonstrated that POS retains effi-
cacy against A fumigatus isolates with POS-MIC of 0.5 mg/L as long 
F I G U R E  1   Posaconazole minimal 
inhibitory concentrations (MICs) 
distributions of most common Mucorales 
species: Rhizopus oryzae, Mucor 
circinelloides, Rhizopus microspores and 
Lichtheimia corymbifera. MICs were 
extracted from Espinel-Ingroff et al36 
MICs were determined according to the 
CLSI method for susceptibility testing of 
moulds (M38-A2)
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as POS exposure is sufficiently high.29,30 Based on these experi-
ments, the required POS exposure (area under the concentration 
time curve (AUC)) in patients can be calculated for isolates with an 
increased MIC. The probability of target attainment for treatment 
of IA using standard dosing of POS tablet is estimated to be ~80% 
for isolates with POS-MIC of 0.25 mg/L and >90% for isolates with 
a POS-MIC of 0.125 mg/L.28 The probability of target attainment 
for a POS-MIC of 0.5 mg/L was 24% and for a POS-MIC ≥0.5 mg/L 
it was 0%.
As determination of the AUC requires multiple sampling mo-
ments, and this AUC is linear correlated to Ctrough concentrations, 
quite often the Ctrough concentrations are used in daily practice as 
surrogate markers.13,28 Monte Carlo simulations estimated that the 
POS Ctrough concentrations needed to be 1.44-1.55 mg/L for iso-
lates with a POS-MIC of 0.25 mg/L and 3.09-3.33 mg/L for isolates 
with a POS-MIC of 0.5 mg/L.28
As the aforementioned in vivo experiments indicated that 
A fumigatus with a POS-MIC of 0.5 mg/L can be treated with 
elevated POS dosing, we hypothesised that targeting high ex-
posure with HD-POS is an oral step-down treatment option for 
azole-resistant IA. Although clinical evidence supporting HD-
POS has not been described, preclinical animal studies and ex-
perience in veterinary medicine provided proof-of-principle for 
its efficiency.28,29
4.2 | Mucormycosis
Limited in vivo models are available that assess POS for the treat-
ment of mucormycosis. A neutropenic mouse model indicated simi-
lar pharmacodynamics for mucormycosis compared to A fumigatus 
infections. An AUC/MIC of 87 was needed to treat Rhizopus oryzae 
infection, which was comparable to the target needed for IA (AUC/
MIC of 76).31 Efficacy of POS showed a dose-response relationship 
in another in vivo model of experimental mucormycosis in which a 
dose of 100 mg/kg/day showed significant reduction of mortality of 
Lichtheimia corymbifera infection.32 Similar dose-response relation-
ships were seen for Mucor species and R oryzae.33,34 Compared to 
A fumigatus isolates, the MICs of Mucorales are often higher with 
a geometric mean CLSI MIC of 0.39 mg/L35 and an epidemiologi-
cal cut-off value of 1 mg/L for L corymbifera, R oryzae and R micro-
spores and 4 mg/L for M circinelloides (Figure 1).36 Furthermore, 
the EUCAST MICs for Mucorales are higher than CLSI MICs for 
most species.37 Taken into account, the similar target AUC/MIC for 
Mucorales as A fumigatus, but higher MICs for Mucorales isolates 
compared to A fumigatus, it seems reasonable to pursue higher than 
normal POS serum concentrations for the treatment of mucormyco-
sis as long as this is not associated with toxicity.13
Posaconazole-oral suspension has been used as salvage therapy 
for mucormycosis with a success rate of approximately 60%-80%.38 
A recently published matched-paired analysis assessed the clinical 
effectiveness and safety of POS tablets and intravenous formula-
tion in comparison with amphotericin B as first-line treatment and 
with POS-OS as salvage treatment for invasive mucormycosis. POS 
tablets and intravenous formulation were effective in terms of treat-
ment response and associated mortality. However, these observa-
tions should be interpreted with caution given the small sample size 
in this study.43 Clinical data on PK/PD are lacking due to limited sus-
ceptibility data from clinical studies.38
4.3 | Dosing and TDM
The pharmacokinetics of posaconazole tablets are best described by 
a one-compartment pharmacokinetic model with sequential zero-
order and first-order absorption and a first-order disposition from 
the central compartment. Recently, several covariates were identified 
influencing bioavailability (like disease state, body weight, formula-
tion), adsorption rate (food status) and clearance (dosing regimen) of 
POS tablets. Only body weight was considered clinically relevant.39 
Knowledge on the PK of POS helps to identify the optimal dose when 
targeting high exposure. Subsequently, an infrastructure is needed 
where one can quickly assess drug concentrations to deploy an adap-
tive approach in terms of dosing. With the new formulations of POS, 
a loading dose is given, which enables early assessment, typically by 
day 3, of POS concentrations. Follow-up samples are measured again 
before the 5th dose of every changed dosage.
The pharmacokinetics described above translates into an ex-
pected doubling of the Ctrough concentration when the dose of POS 
tablet or IV formulation is doubled. For example, when the Ctrough 
concentration is 1.5 mg/L, increasing the dose from 300 mg once 
daily to 300 mg twice daily can be expected to lead to a serum con-
centration of 3 mg/L. For safety reasons, we advise to increase the 
dose with no more than 200 mg per step.
4.4 | Inhibitory potential of HD-POS
Posaconazole is a strong CYP3A4 inhibitor, and the clinician should 
therefore also remain vigilant for drug interactions. In our case se-
ries, we had two patients with significant interactions. Toxicity of 
HD-POS in combination with vincristine was seen in a child with 
ALL, resulting in hepatotoxicity, convulsions and hypertension 
which might be attributed to the inhibition of CYP3A4 as well as 
P-gp resulting in increased levels of vincristine.40 Another alloge-
neic stem cell transplant patient developed IA despite prophylaxis 
with voriconazole. Treatment with L-AmB was started but switched 
to HD-POS for progressive renal impairment. POS Ctrough concen-
tration was 5.2 mg/L. After the patient was treated with panobi-
nostat, a histone deacetylase (HDAC) inhibitor, grade 4 leukopenia 
developed. After 4 weeks of persisting grade 4 leukopenia, POS 
treatment was stopped as presumed culprit and leukopenia im-
proved. This interaction could have been predicted based on the 
interaction of panobinostat with ketoconazole where panobinostat 
maximum serum concentrations were increased by an average of 
1.6-fold.41
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4.5 | Safety monitoring for HD-POS
We propose that the following safety measures are taken if HD-
POS is used as a treatment strategy. At least the following labo-
ratory tests should be performed twice weekly during the first 
2 weeks and as long as the POS dosage is being increased: elec-
trolytes, renal clearance, haemoglobin, leucocyte differentiation, 
thrombocytes and liver enzymes. Posaconazole may cause QT pro-
longation. Therefore, an ECG should be recorded before the start of 
HD-POS as well as during treatment. If no laboratory abnormalities 
possibly related to POS are observed the monitoring interval can 
be increased.
In conclusion, registration of new antifungals with efficacy 
against azole-resistant A fumigatus is expected to take several 
more years. Therefore, targeting high serum concentrations of POS 
using the tablet or IV formulation is, in our point of view, a possi-
ble step-down option in patients with azole-resistant IA as long as 
the POS-MIC is <1 mg/L and for patients treated for mucormycosis 
with L-AmB. It should only be used when close monitoring for AE is 
implemented as described above in conjunction with TDM and when 
the benefits are likely to outweigh the risks.
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